Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Vigneri

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Ecancermedicalscience|November 4, 2020
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysisVittorio Gebbia, Marco Maria Aiello, Giuseppe Banna, et al.
Carcinogenesis|January 22, 2014
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferationMichele Massimino, Maria Letizia Consoli, Maria Mesuraca, et al.
BMC Cancer|February 13, 2022
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancerSilvia R Vitale, Kirsten Ruigrok-Ritstier, A Mieke Timmermans, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 16, 2010
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cellsMatilde D'Asaro, Carmela La Mendola, Diana Di Liberto, et al.
Insights Into Imaging|June 3, 2021
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerationsPietro Valerio Foti, Mario Travali, Renato Farina, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancerRoberto Buonaiuto, Federica Martorana, Paola Marino, et al.
Frontiers in Oncology|September 26, 2022
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approachAlessandra Fabi, Giuseppe Buono, Emilio Bria, et al.
Frontiers in Oncology|April 4, 2022
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic ApplicationsElena Tirrò, Michele Massimino, Giuseppe Broggi, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Annals of Hematology|October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemiaMario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Ecancermedicalscience|November 4, 2020
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysisVittorio Gebbia, Marco Maria Aiello, Giuseppe Banna, et al.
Carcinogenesis|January 22, 2014
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferationMichele Massimino, Maria Letizia Consoli, Maria Mesuraca, et al.
BMC Cancer|February 13, 2022
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancerSilvia R Vitale, Kirsten Ruigrok-Ritstier, A Mieke Timmermans, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 16, 2010
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cellsMatilde D'Asaro, Carmela La Mendola, Diana Di Liberto, et al.
Insights Into Imaging|June 3, 2021
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerationsPietro Valerio Foti, Mario Travali, Renato Farina, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancerRoberto Buonaiuto, Federica Martorana, Paola Marino, et al.
Frontiers in Oncology|September 26, 2022
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approachAlessandra Fabi, Giuseppe Buono, Emilio Bria, et al.
Frontiers in Oncology|April 4, 2022
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic ApplicationsElena Tirrò, Michele Massimino, Giuseppe Broggi, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Annals of Hematology|October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemiaMario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Pageof 15